First Trust Advisors
AMLX icon

First Trust Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

First Trust Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-221,626
Closed -$718K – 2557
2024
Q3 		$718K Buy
221,626
+82,529
+59% +$186K ﹤0.01% 2093
2024
Q2 		$264K Sell
139,097
-31,381
-18% -$60.8K ﹤0.01% 2223
2024
Q1 		$484K Buy
170,478
+153,098
+881% +$2M ﹤0.01% 2157
2023
Q4 		$256K Buy
+17,380
New +$266K ﹤0.01% 2260
2023
Q3 		– Sell
-54,115
Closed -$1.17M – 2348
2023
Q2 		$1.17M Buy
54,115
+26,798
+98% +$724K ﹤0.01% 1936
2023
Q1 		$801K Sell
27,317
-29,503
-52% -$1.02M ﹤0.01% 2023
2022
Q4 		$2.1M Buy
+56,820
New +$2.02M ﹤0.01% 1677

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

First Trust Advisors's AMLX Position: Q4 2024 in Review

First Trust Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 221,626 shares — an estimated $718K sold.

First Trust Advisors first reported a position in AMLX in Q4 2022 and held it in 7 quarters. The position peaked at $2.1M in Q4 2022. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

  • First Trust Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • First Trust Advisors sold 221,626 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $718K.
  • First Trust Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • First Trust Advisors's Amylyx Pharmaceuticals position peaked at $2.1M in Q4 2022.
  • 122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on First Trust Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.